Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

April 23, 2024

https://www.globenewswire.com/news-release/2024/04/23/2867657/0/en/Tarsus-Strengthens-Financial-Position-and-Refinances-Existing-Debt-with-200-Million-Non-dilutive-Financing-Commitment-from-Pharmakon.html

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital available at the company’s option in three tranches through specified time windows, the last ending in December 2025.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.